Although magnolol (Mag), an anti-inflammatory
natural compound,
has been demonstrated to play protective effects on ulcerative colitis
(UC), its application as an alternative therapeutic reagent for UC
treatment is still greatly impeded due to its poor stability in the
gastrointestinal tract and insufficient accumulation in the inflamed
colon lesion. Nano-/microsized drug delivery systems can potentially
overcome some challenges regarding the oral administration of phytochemicals,
which still confront premature early drug release, degradation of
NPs, or the sustained drug release of MPs. In this study, we primarily
loaded Mag into the core–shell zein-based nanoparticles with
chondroitin sulfate coating (Mag@CS-Zein NPs) with an average size
of 142.27 ± 5.11 nm, showing significant macrophage-targeting
and enhanced colon epithelial cellular uptake capacity. Then, we embedded
Mag@CS-Zein NPs into hydrogel microspheres via an electrospraying
technology. The Mag@CS-Zein NPsinMPs presented a uniform-sized sphere
with an average size of 164.36 ± 6.29 μm and sustained
drug-release profiles. Compared to CS-Zein NPs, the developed CS-Zein
NPsinMPs exhibited prolonged colon retention on the inflammatory surface,
as seen from ex vivo and in vivo imaging fluorescence adhesion experiments. Based on the advantage
of the combination of hybrid nanoparticles-in-microparticles, oral
administration of Mag@CS-Zein NPsinMPs significantly alleviated colitis
symptoms in DSS-treated mice by regulating the expression levels of
proinflammatory cytokines (TNF-α, IL-6, and IL-1β) and
anti-inflammatory cytokines (IL-10) and factor accelerated colonic
mucosal barrier repair via upregulating the expression of ZO-1 and
occludin. This study provides great insights into the oral drug delivery
of natural compounds for UC therapy.